Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression
© Peng et al. 2015
Received: 2 April 2015
Accepted: 29 July 2015
Published: 8 August 2015
Long noncoding RNAs (lncRNAs) have recently emerged as important regulators in governing fundamental biological processes, and many of which are likely to have functional roles in tumorigenesis. Maternally expressed gene 3 (MEG3) gene encodes a lncRNA whose expression is lost in an expanding list of primary human tumors and tumor cell lines, however its biological role and regulatory mechanism in gastric cancer (GC) development and progression are poorly defined.
Quantitative RT-PCR analysis was used to determine whether aberrant MEG3 expression was associated with GC patients pTNM stage and pM state. Furthermore, the effect of ectopic expression of MEG3 on cell proliferation, migration, invasion and cell apoptosis was assessed by using CCK-8, wound healing, transwell invasion assays and flow cytometric analysis, respectively, in GC cell lines HGC-27 and MGC-803. Moreover, the competing endogenous RNA (ceRNA) activity of MEG3 on miR-181a was investigated via luciferase reporter assay and immunoblot analysis.
MEG3 is decreased in GC patients and cell lines, and its expression was associated with metastatic GC. Furthermore, ectopic expression of MEG3 in HGC-27 and MGC-803 cells inhibited cell proliferation, migration, invasion, and promoted cell apoptosis, which might be due to MEG3 sequestering oncogenic miR-181 s in GC cells. Furthermore, MEG3 could up-regulated Bcl-2 via its competing endogenous RNA (ceRNA) activity on miR-181a.
These findings suggest that lncRNA MEG3, a ceRNA of miR-181 s, could regulate gastric carcinogenesis and may serve as a potential target for antineoplastic therapies.
The ENCODE (encyclopedia of DNA elements) project showed that ~80 % of the human genome is transcribed to RNA, with only ~2 % being responsible for protein coding. According to their size, non-coding RNAs (ncRNAs) are classified into small ncRNAs and long ncRNAs (lncRNAs). Small ncRNAs include siRNAs, piRNAs, and miRNAs that have a length of less than 200 nucleotides (nt). LncRNAs are greater than 200 nt in length, frequently up to hundred kb. Recent studies have revealed that a number of lncRNAs have essential roles in a diverse range of cellular functions such as development, differentiation, and cell fate as well as disease pathogenesis, causing a paradigm change in our understanding of gene regulation [1–3]. For example, the metastasis-associated lungadenocarcinoma transcript1 (MALAT1), also known as NEAT2, has been implicated in several studies as having an important role in metastasis [4–6]. H19 dysregulation has also been implicated in a variety of other cancers, as colorectal cancer, hepatocellular carcinoma, breast cancer, and bladder cancer [7–11]. Additionally, the HOX antisense intergenic RNA (HOTAIR) was shown to be overexpressed up to 2000 fold in breast cancer metastases, with its expression being a significant predictor of metastasis and death independent of other risk factors such as tumor size, stage, and hormone receptor status [12–14]. LncRNA, colon cancer associated transcript 2 (CCAT2), was found to have increased expression in metastatic colorectal cancer patient tumor samples. The lncRNA gastric cancer associated transcript 1 (GACAT1), was found to be expressed at lower levels in gastric cancer tissues compared to corresponding normal tissues [15, 16]. Identification of differential expression, while extremely useful, is only the first step in the elucidation of the lncRNA-based molecular mechanisms capable of regulating tumorigenesis. Exploration of the function and involvement of lncRNA in gene expression may become a key development in exploring the molecular mechanisms of cancer.
Gastric cancer (GC) ranks the fourth most commonly diagnosed cancer and the second lethal malignancy worldwide, and is the most common gastrointestinal malignancy in East Asia, Eastern Europe, and parts of Central and South America [17–19]. GC is diagnosed at advanced stage accompanied by malignant proliferation and metastasis. In spite of the progress in chemotherapy, radiotherapy and surgical techniques for GC in recent years, the survival rate of GC patients remains unsatisfactory . Although many oncogenes or tumor suppressors have been identified as key players underlying tumorigenesis of GC, however, almost no commonly-accepted biomarkers have been established to facilitate the comprehensive management of patients [21, 22]. Therefore, the identification of the new regulators and therapeutic targets for GC and a detailed understanding of the molecular mechanisms underlying gastric carcinogenesis will be important to understand the molecular biology of tumor and its progression. The significance of lncRNAs in human GC was realized by Yang and colleagues elucidating the contributions of H19 to GC, suggesting a link between lncRNAs and GC . Following this study, several groups focused on the aberrant expression of lncRNAs during GC, and accumulating studies indicated that specific lncRNAs had potential biological and clinical relevance in GC . Therefore, it is of great clinical value to identify cancer-associated lncRNAs and investigate their molecular and biological functions for GC prevention, diagnosis, and therapeutic targets.
In the current study, we showed that a lncRNA, maternally expressed gene 3 (MEG3) is decreased in GC patients and cell lines, and its expression was associated with metastatic GC. We also showed that MEG3 inhibited GC cell proliferation, migration and invasion by operating as a competing endogenous RNA (ceRNA) for the miR-181 microRNA (miRNA) family. Furthermore, MEG3 affected GC cell phenotypes in a miR-181 sites-dependent manner, which occurs without changes in the levels of miR-181 isoforms, suggesting that MEG3 regulates miR-181 activity by altering miRNA targeting. B cell lymphoma-2 (Bcl-2) was subsequently validated as a downstream target of MEG3 ceRNA function, and was important for MEG3 to regulate GC progression. Taken together, these results suggest that MEG3 could regulate gastric carcinogenesis as a ceRNA and may serve as a potential target for antineoplastic therapies.
Materials and methods
Gastric cancer tissues
Gastric cancers and their morphologically normal tissue (located >3 cm away from the tumor)were obtained between November 2011 and November 2014 from 50 gastric cancer patients undergoing surgery at Cancer Hospital of Chinese Academy of Medical Sciences. Tissue samples were cut into two parts, one was fixed with 10 % formalin for histopathological diagnosis, and the other was immediately snap-frozen in liquid nitrogen, and stored in liquid nitrogen until RNA extraction. This group consisted of 38 males and 12 females with a median age of 58 years (range, 32–69 years). The use of the tissue samples for all experiments was approved by all the patients and by Ethics Committee of the institution.
Tissue RNA isolation and qRT-PCR
Total RNA was extracted from the cells and tissues using Trizol reagent (Invitrogen, CA, USA), according to the manufacturer’s instructions. RT-qPCR assay was conducted to detect the level of RNA transcripts. Briefly, cDNA was synthesised by M-MLV reverse transcriptase (Invitrogen) from 5 ug of total RNA. Oligo (dT18) RT primer was used for the reverse transcription of mRNA and lncRNA. Stem-poop RT primer was used for the reverse transcription of miR-181a. Quantitative RT-qPCR was performed on the Bio-rad CFX96 real-time PCR System (Bio-rad, Foster City, CA, USA) using KAPA PROBE FAST qPCR Kits (Kapa Biosystems, MA, USA) and TaqMan probes (Invitrogen) with the following cycling conditions: 95 °C for 10 min (initial denature); then 40 cycles of 95 °C for 15 sec, 60 °C for 60 sec. The miR-33b specific forward primer sequence was designed on the basis of miRNA sequences obtained from the miRBase database. Human GAPDH and U6 snRNA were used for mRNA/lncRNA and miRNA normalization, respectively.
Cell cultures and cell transfection
A total of 6 human gastric cancer cell lines MGC-803, HGC-27, MKN-45, SGC-7901, BGC-823 and AGS were examined in this study. The HGC-27, MKN-45, SGC-7901 cell lines were provided by American Type Culture Collection (ATCC; Manassas, VA, USA), and were maintained in RPMI 1640 medium (PAA) supplemented with 10 % FBS (PAA). The MGC-803, BGC-823 and AGS cell lines were purchased from the Cell Resource Center of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China), and was propagated in Dulbecco’s modified Eagle medium (Gibco; Invitrogen; Life Technologies, Germany), supplemented with 10 % fetal bovine serum (FBS; PAA, Pasching, Austria) and streptomycin (100 μg/ml), penicillin (100 U/ml). The human gastric cancer cell lines HGC-27 and MGC-803 were transfected with miRNA mimic, mimic control, miRNA inhibitor, inhibitor control, (Scramble; GenePharma; Shanghai, China) at a final concentration of 25 nmol/L using DharmaFECT 1 (Dharmacon; USA) in accordance with the manufacturer’s instructions. The same cells were transfected with different MEG3 constructs at a final concentration of 2 μg/uL using Lipo2000 (Invitrogen; USA) in accordance with the manufacturer’s instructions.
Cell proliferation assay
Hgc-27 and MGC-803 cells were incubated in 10 % CCK-8 (DOJINDO, Japan) diluted in normal culture medium at 37 °C until visual color conversion occurred. Proliferation rates were determined at 0, 24, 48, 72, 96 hours after transfection. The absorbance of each well was measured with a microplate reader set at 450nM and 630nM. All experiments were performed in quadruplicate.
Cell apoptosis assay
In order to detect the apoptosis of HGC-27 and MGC-803 cells, flow cytometric analysis was applied with Annexin V-FITC/PI Apoptosis Detection Kit (KeyGEN Biotech, Nanjing, China) according to the manufacturer’s instructions. The acquisition and analysis were performed using MoFlow (Beckman Coulter, Atlanta, GA, USA).
Cell migration and invasion assays
HGC-27 and MGC-803 cells were grown to confluence on 12-well plastic dishes and treated with miRNA mimics or Scramble. Then 24 hours after transfection, linear scratch wounds (in triplicate) were created on the confluent cell monolayers using a 200 μL pipette tip. To remove cells from the cell cycle prior to wounding, cells were maintained in serum-free medium. To visualize migrated cells and wound healing, images were taken at 0, 24, 48 hours. A total of ten areas were selected randomly from each well and the cells in three wells of each group were quantified.
For the invasion assays, after 24 hours transfection, 1 × 105 HGC-27or MGC-803 cells in serum-free media were seeded onto the transwell migration chambers (8 μm pore size; Millipore, Switzerland) which coated with the upper chamber of an insert coated with Matrigel (Sigma-Aldrich, USA). Media containing 20 % FBS were added to the lower chamber. After 24 hours, the noninvading cells were removed with cotton wool, Invasive cells located on the lower surface of the chamber were stained with May-Grunwald-Giemsa stain (Sigma-Aldrich, USA) and counted using a microscope (Olympus, Tokyo, Japan). Experiments were independently repeated three times.
Luciferase reporter assay
HGC-27 cells were co-transfected with 0.4 μg of pMIR constructs containing the wild type MEG3 or diverse mutant MEG3, along with 0.02 μg of the pRL-TK control vector and miR-181a mimic or mimic control. Cells were harvested 48 h post-transfection and assayed with Dual Luciferase Assay (Promega, WI, USA) according to the manufacturer’s instructions. All transfection assays were carried out in triplicate.
Immunoblot analysis was carried out using standard methods. Proteins were separated by 10 % SDS-PAGE, and transferred onto PVDF membranes (Millipore Corporation, Billerica MA, USA). Membranes were blocked overnight with 5 % non-fat dried milk for 2 h and incubated with anti-Bcl-2 antibody (Abcam, ab117115) at 1:2000 dilution; anti-GAPDH antibody (Proteintech) at 1:50,000 dilution overnight at 4 °C. After washing with TBST (10 mM Tris, pH 8.0, 150 mM NaCl, and 0.1 % Tween20), the membranes were incubated for 2 h at room temperature with goat anti-rabbit antibody (Zsgb-bio, Beijing, China) at 1:20000.
RNA pull-down by MS2-MBP
Maltose-binding protein (MBP)-affinity purification was used to identify miRNAs that associated with lncRNA MEG3. The MS2-MBP protein was expressed and purified from E. coli following a protocol from the Steitz lab. Three bacteriophage MS2 coat protein-binding sites (5′-cgtacaccatcagggtacgagctagcccatggcgtacaccatcagggtacgactagtagatctcgtacaccatcagggtacg-3’) were inserted downstream of MEG3 by site-directed mutagenesis using Stratagene’s QuikChange Site-Directed Mutagenesis Kit. To obtain miRNAs associated with MEG3, HGC-27 cells were transfected with MS2-containing MEG3 constructs, and 10 million cells were used for each immunoprecipitation assay. The cells were harvested 48 h post-transfection and subjected to RNA pull-down analysis as described elsewhere.
Aberrant expression of lncRNA MEG3 in human GC tissues and cell lines
MEG3 inhibits GC cell proliferation, migration and invasion
Based on the correlation between MEG3 expression and metastatic factors, we proposed that this lncRNA might play an important role in regulating cell migration and invasion of GC cells. To test this hypothesis, cell migration and invasion assays were performed in HGC-27 and MGC-803 cells transfected with pCMV-MEG3 or pCMV6. As a result, the wound healing assay showed that cell migration was inhibited in MEG3-overexpressed GC cells compare to the controls (Fig. 2d). Moreover, transwell invasion assay indicated a significant reduction in cell invasiveness after pCMV-MEG3 transfection into both HGC-27 and MGC-803 cells (Fig. 2e). Taken together, these results suggest that MEG3 may act as a tumor suppressor through inhibiting cell proliferation, migration and invasion, and promoting cell apoptosis in GC.
MEG3 is physically associated with miR-181 family
miR-181a function as an oncogene in GC
Additionally, the wound healing assay showed that cell migration was inhibited in miR-181a inhibitor-transfected HGC27 and MGC-803 cells compare to the inhibitor control-transfected ones (Fig. 4e), suggesting the stimulating effects of miR-181a on tumor cell migration. To detect whether miR-181a possesses the ability to inhibit cell invasion, transwell invasion assay was performed. As expected, there was significant reduction in cell invasiveness after miR-181a inhibitor transfection in both HGC-27 and MGC-803cell lines (Fig. 4 f). Taken together, these results indicated the oncogenic roles of miR-181a in GC cells, which was opposite to its ceRNA MEG3.
MEG3 ceRNA activity regulates Bcl-2 expression
Maternally expressed gene 3 (MEG3) is an imprinted gene belonging to the imprinted DLK1–MEG3 locus located at chromosome 14q32.3 in human genome. Its mouse ortholog, Meg3, also known as gene trap locus 2 (Gtl2), is located at distal chromosome 12 . Mice carrying the maternal deletion of the Meg3 region died perinatally and had major skeletal muscle defects. MEG3 is expressed in many normal tissues, and the loss of MEG3 expression has been found in various types of human tumors, including in 25 % of neuroblastomas, 81 % of hepatocellular cancers, and 82 % of gliomas [26, 27]. However, the involvement of MEG3 in gastric cancer has not been reported. Our findings indicated that MEG3 was down-regulated in GC tissues, and a lower level of MEG3 was associated with tumor stage and metastasis. Functional analysis confirmed the pleiotropic effects of MEG3 on GC cell proliferation, migration and invasion. Therefore, lncRNA MEG3 was determined as a novel tumor suppressor in human GC.
Although a vast set of lncRNA transcripts are differentially expressed during development where many of them play critical roles, most of them have not yet been studied in mechanistic details. Till now, a majority of the lncRNAs have been linked with epigenetic modulation of gene expressions, they can also regulate gene expression by transcriptional or post transcriptional modes. In recent years it has been discovered that endogenous lncRNAs can influence post-transcriptional regulation by interfering with the miRNA pathways, by acting as competing endogenous RNAs (ceRNAs) [28–30]. These lncRNAs have miRNA responsive elements (MRE) and act as miRNA sponges to control endogenous miRNAs available for binding with their target mRNAs, thus reducing the repression of these mRNAs . It also suggests that these ceRNAs are implicated in many biological processes and the disruption of the equilibrium of ceRNAs and miRNAs can be critical for ceRNA activity and promotion of diseases like cancer. For example, lncRNA PTEN-P1 could block miR-19b and miR-20a from binding to PTEN tumor suppressor in prostate cancer, glioblastoma, and melanoma, and disruption in the network leads to tumorigenesis in many cases [28, 31]. HULC lncRNA also acts as ceRNA of the protein coding gene PRKACB that induces activation of CREB to modulate self-regulation in hepatocellular carcinoma . In a recent study, lncRNA-activated by TGF-b (lncRNA-ATB) was upregulated in hepatocellular carcinoma metastases and associated with poor prognosis . lncRNA-ATB upregulated ZEB1 and ZEB2 by competitively binding the miR-200 family and then induced EMT and invasion . Additionally, Hmga2 promotes lung carcinogenesis both as a protein-coding gene and as a ceRNA dependent upon the presence of let-7 sites . Thus, The intricate networks of ceRNAs in cells are a fascinating new subject of study for researchers working towards understanding the language of RNA molecules and gene expression networks in tumorigenesis.
In this study, we report that lncRNA MEG3 inhibits GC cell proliferation, migration and invasion by competitively binding the miR-181 family, upregulating Bcl-2, and then suppressing gastric carcinogenesis (Fig. 5d). The dysregulation of MEG3 has been reported in many cancer types and its tumor suppressor activity was mediated by interaction with either p53-dependent transcription, or Rb-related pathways. Our studies revealed a novel ceRNA activity of MEG3 in human GC cells. Although much of MEG3 ceRNA activity is driven by overexpression of Bcl-2 in GC, there are likely to be additional MEG3 ceRNA targets to be found in future studies.
Taken together, our research demonstrated that MEG3 acted as a key regulator in human gastric carcinogenesis and revealed roles of MEG3 in regulating miR-181-Bcl2 axis. The findings of this study have significant implications regarding our understanding of GC pathogenesis. Moreover, the pleiotropic effects of MEG3 on GC tumorigenesis suggest that it could be an effective target for antineoplastic therapies.
We thanked Dr. Yi Wang from Cancer Hospital of Chinese Academy of Medical Sciences for the GC samples. This work was supported by grants from the National Natural Science Foundation of China (2011, 91129716, to J.Y.; 2015, 31471227, to F.W.), the Beijing Municipal Science & Technology Commission (2010B071, to J.Y.).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, et al. A long noncoding RNA connects c-Myc to tumor metabolism. Proc Natl Acad Sci. 2014;111:18697–702.PubMed CentralPubMedView ArticleGoogle Scholar
- Haemmerle M, Gutschner T. Long Non-Coding RNAs in Cancer and Development: Where Do We Go from Here? Int J Mol Sci. 2015;16:1395–405.PubMed CentralPubMedView ArticleGoogle Scholar
- Chen LL, Zhao JC. Functional analysis of long noncoding RNAs in development and disease. Adv Exp Med Biol. 2014;825:129–58.PubMedView ArticleGoogle Scholar
- Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014;111:736–48.PubMedView ArticleGoogle Scholar
- Wang J, Su L, Chen X, Li P, Cai Q, Yu B, et al. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. Biomed Pharmacother. 2014;68:557–64.PubMedView ArticleGoogle Scholar
- Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther. 2014;15:806–14.PubMed CentralPubMedView ArticleGoogle Scholar
- Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012;279:3159–65.PubMedView ArticleGoogle Scholar
- Medrzycki M, Zhang Y, Zhang W, Cao K, Pan C, Lailler N, et al. Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res. 2014;74:6463–73.PubMedView ArticleGoogle Scholar
- Li H, Yu B, Li J, Su L, Yan M, Zhu Z, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5:2318–29.PubMed CentralPubMedGoogle Scholar
- Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J. 2013;280:1709–16.PubMedView ArticleGoogle Scholar
- Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 2013;333:213–21.PubMedView ArticleGoogle Scholar
- Wu Y, Zhang L, Wang Y, Li H, Ren X, Wei F, et al. Long noncoding RNA HOTAIR involvement in cancer. Tumour Biol. 2014;35:9531–8.PubMedView ArticleGoogle Scholar
- Yan TH, Lu SW, Huang YQ, Que GB, Chen JH, Chen YP, et al. Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladdercancer. Tumour Biol. 2014;35:10249–57.PubMedView ArticleGoogle Scholar
- Wu ZH, Wang XL, Tang HM, Jiang T, Chen J, Lu S, et al. Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep. 2014;32:395–402.PubMedGoogle Scholar
- Ling H, Spizzo R, Atlasi Y, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23:1446–61.PubMed CentralPubMedView ArticleGoogle Scholar
- Qiu M, Xu Y, Yang X, Wang J, Hu J, Xu L, et al. CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumour Biol. 2014;354:5375–80.View ArticleGoogle Scholar
- Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17–20.PubMed CentralPubMedGoogle Scholar
- Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. International journal of cancer. Journal international du cancer. 2005;125:666–73.View ArticleGoogle Scholar
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedView ArticleGoogle Scholar
- Kagawa S, Shigeyasu K, Ishida M, Watanabe M, Tazawa H, Nagasaka T, et al. Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. World J Gastroenterol. 2014;20:17796–803.PubMed CentralPubMedGoogle Scholar
- Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39–48.PubMed CentralPubMedView ArticleGoogle Scholar
- Saito T, Kurokawa Y, Takiguchi S, Mori M, Doki Y. Current status of function-preserving surgery for gastric cancer. World J Gastroenterol. 2014;20:17297–304.PubMed CentralPubMedView ArticleGoogle Scholar
- Cai B, Song XQ, Cai JP, Zhang S. HOTAIR: a cancer-related long non-coding RNA. Neoplasma. 2014;61:379–91.PubMedView ArticleGoogle Scholar
- Ouyang YB, Lu Y, Yue S, Giffard RG. miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion. 2012;12:213–9.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res. 2010;70:2350–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Benetatos L, Vartholomatos G, Hatzimichael E. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer. 2011;129:773–9.PubMedView ArticleGoogle Scholar
- Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;48:R45–53.PubMed CentralPubMedView ArticleGoogle Scholar
- Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, et al. Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression. Mol Cancer Ther. 2014;13:3086–97.PubMedView ArticleGoogle Scholar
- Sen R, Ghosal S, Das S, Balti S, Chakrabarti J. Competing endogenous RNA: the key to posttranscriptional regulation. Scientific World Journal. 2014;2014:896206.PubMed CentralPubMedView ArticleGoogle Scholar
- Chiu HS, Llobet-Navas D, Yang X, Chung WJ, Ambesi-Impiombato A, Iyer A, Kim HR, Seviour EG, Luo Z, Sehgal V et al. Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Res 2014, pii: gr.178194.114.Google Scholar
- Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38:5366–83.PubMed CentralPubMedView ArticleGoogle Scholar
- Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666–81.PubMedView ArticleGoogle Scholar
- Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505:212–7.PubMedView ArticleGoogle Scholar